Condition
FTD clinical trials and research
As of November 12, 2026, Find a Trial lists 5 FTD clinical trials that are recruiting, at sites in 11 countries (most in Italy (3), China (1), France (1)). By phase: Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 11Countries
Newest FTD clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Temporal Interference Stimulation for cognitive impairment | — | Tianjin, Tianjin Municipality | Recruiting | Jun 11, 2026 |
| Magnetic brain stimulation for frontotemporal lobar degeneration | — | Brescia, Italy | Recruiting | Jan 5, 2026 |
| Omics-based profiling to find disease mechanisms and biomarkers in Alzheimer’s, Parkinson’s, FTD, and related dementias | — | Genoa, Genoa | Recruiting | Nov 19, 2025 |
| Gene therapy for Frontotemporal Dementia with Progranulin Mutations | Phase 1/2 | Columbus, Ohio and 18 other locations | Recruiting | Oct 3, 2023 |
| Using neurofilament light chains to differentiate cognitive impairments in psychiatric and neurodegenerative diseases | — | Bron and 1 other locations | Recruiting | Jul 1, 2021 |
All recruiting trials (5)
-
Temporal Interference Stimulation for cognitive impairment
This study tests a non-invasive brain stimulation method called temporal interference stimulation to see if it can improve thinking and memory in people with mild cognitive impairment, Alzheimer's disease, or frontotemporal dementia.
-
Magnetic brain stimulation for frontotemporal lobar degeneration
This trial will try repetitive transcranial magnetic stimulation (rTMS) to see if it is safe and helps people with frontotemporal lobar degeneration or asymptomatic people at risk.
-
Omics-based profiling to find disease mechanisms and biomarkers in Alzheimer’s, Parkinson’s, FTD, and related dementias
This project will use advanced omics tests (genetics, gene expression, proteins, and metabolites) to try to find biological markers and disease mechanisms in people with Alzheimer’s, Parkinson’s, frontotemporal and young-onset dementias, or mild cognitive impairment.
-
Gene therapy for Frontotemporal Dementia with Progranulin Mutations
This study is testing a one-time gene therapy to see if it can safely help people with Frontotemporal Dementia caused by a specific gene mutation by restoring a protein in the brain.
-
Using neurofilament light chains to differentiate cognitive impairments in psychiatric and neurodegenerative diseases
This study is testing if a specific protein in the blood can help tell the difference between cognitive problems caused by mental health issues and those caused by brain diseases like Alzheimer's or dementia.
Related topics
Quick answers
How many FTD clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 11 countries. The most sites are in Italy (3 trials), China (1 trial), France (1 trial), Belgium (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.